Literature DB >> 20417774

Interstitial plasmin activity with epsilon aminocaproic acid: temporal and regional heterogeneity.

Daryl L Reust1, Scott T Reeves, James H Abernathy, Jennifer A Dixon, William F Gaillard, Rupak Mukherjee, Christine N Koval, Robert E Stroud, Francis G Spinale.   

Abstract

BACKGROUND: Epsilon aminocaproic acid (EACA) is used in cardiac surgery to modulate plasmin activity (PLact). The present study developed a fluorogenic-microdialysis system to measure in vivo region specific temporal changes in PLact after EACA administration.
METHODS: Pigs (25 to 35 kg) received EACA (75 mg/kg, n = 7) or saline in which microdialysis probes were placed in the liver, myocardium, kidney, and quadricep muscle. The microdialysate contained a plasmin-specific fluorogenic peptide and fluorescence emission, which directly reflected PLact, determined at baseline, 30, 60, 90, and 120 minutes after EACA/vehicle infusion.
RESULTS: Epsilon aminocaproic acid caused significant decreases in liver and quadricep PLact at 60, 90, 120 minutes, and at 30, 60, and 120 minutes, respectively (p < 0.05). In contrast, EACA induced significant biphasic changes in heart and kidney PLact profiles with initial increases followed by decreases at 90 and 120 minutes (p < 0.05). The peak EACA interstitial concentrations for all compartments occurred at 30 minutes after infusion, and were fivefold higher in the renal compartment and fourfold higher in the myocardium, when compared with the liver or muscle (p < 0.05).
CONCLUSIONS: Using a large animal model and in vivo microdialysis measurements of plasmin activity, the unique findings from this study were twofold. First, EACA induced temporally distinct plasmin activity profiles within the plasma and interstitial compartments. Second, EACA caused region-specific changes in plasmin activity profiles. These temporal and regional heterogeneic effects of EACA may have important therapeutic considerations when managing fibrinolysis in the perioperative period. Copyright (c) 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20417774      PMCID: PMC2890310          DOI: 10.1016/j.athoracsur.2010.01.051

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  32 in total

Review 1.  Natural and synthetic antifibrinolytics in adult cardiac surgery: efficacy, effectiveness and efficiency.

Authors:  J F Hardy; S Bélisle
Journal:  Can J Anaesth       Date:  1994-11       Impact factor: 5.063

2.  Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid.

Authors:  M E Dentz; T F Slaughter; J B Mark
Journal:  Anesthesiology       Date:  1995-02       Impact factor: 7.892

3.  Direct photometric or fluorometric assay of proteinases using substrates containing 7-amino-4-trifluoromethylcoumarin.

Authors:  R E Smith; E R Bissell; A R Mitchell; K W Pearson
Journal:  Thromb Res       Date:  1980 Feb 1-15       Impact factor: 3.944

Review 4.  Clinical pharmacology of aminocaproic and tranexamic acids.

Authors:  I M Nilsson
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

5.  Fatal aortic thrombosis in a neonate during infusion of epsilon-aminocaproic acid.

Authors:  J R Hocker; K L Saving
Journal:  J Pediatr Surg       Date:  1995-10       Impact factor: 2.545

Review 6.  Clinical application of inhibitors of fibrinolysis.

Authors:  M Verstraete
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

7.  epsilon-Aminocaproic acid plasma levels during cardiopulmonary bypass.

Authors:  E Bennett-Guerrero; J G Sorohan; A T Canada; L Ayuso; M F Newman; J G Reves; M G Mythen
Journal:  Anesth Analg       Date:  1997-08       Impact factor: 5.108

8.  Rhabdomyolysis induced by epsilon-aminocaproic acid.

Authors:  B D Seymour; M Rubinger
Journal:  Ann Pharmacother       Date:  1997-01       Impact factor: 3.154

9.  The pharmacokinetics of epsilon-aminocaproic acid in children undergoing surgical repair of congenital heart defects.

Authors:  Douglas G Ririe; Robert L James; James J O'Brien; Yonggu A Lin; Judy Bennett; David Barclay; Michael H Hines; John F Butterworth
Journal:  Anesth Analg       Date:  2002-01       Impact factor: 5.108

Review 10.  Managing fibrinolysis without aprotinin.

Authors:  L Henry Edmunds
Journal:  Ann Thorac Surg       Date:  2010-01       Impact factor: 4.330

View more
  1 in total

1.  Continuous localized monitoring of plasmin activity identifies differential and regional effects of the serine protease inhibitor aprotinin: relevance to antifibrinolytic therapy.

Authors:  Daryl L Reust; Jennifer A Dixon; Richard A McKinney; Risha K Patel; William T Rivers; Rupak Mukherjee; Robert E Stroud; Karen Madden; Kevin Groves; Milind Rajopadhye; Scott T Reeves; James H Abernathy; Francis G Spinale
Journal:  J Cardiovasc Pharmacol       Date:  2011-04       Impact factor: 3.105

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.